Search All Tech Briefings


Search technology briefings produced by NIHR Innovation Observatory. These are short reports on new or repurposed medicines that we have already sent to our stakeholders. Only those technologies (medicines) that are within the scope of our stakeholders will have a technology briefing available.  Search our technology briefings by intervention (drug or device), specific indication (disease or condition), or general therapeutic area.

| 145 Results

Title
Intervention Indication Therapeutic Area Year Actions
Atezolizumab in addition to chemotherapy for stage IV non-squamous non-small-cell lung cancer – first line Atezolizumab (Tecentriq; MPDL3280A) Non-small-cell lung cancer (NSCLC) Lung and Respiratory Cancer 2018 View  |  Download
Atezolizumab in Addition to Chemotherapy for Stage IV Squamous Non-Small Cell Lung Cancer – First Line Atezolizumab (Tecentriq; MPDL3280A) Non-small-cell lung cancer (NSCLC) Lung and Respiratory Cancer 2018 View  |  Download
Atezolizumab in combination with cobimetinib for BRAF wild-type metastatic melanoma – first line Atezolizumab (Tecentriq; MPDL3280A) , Cobimetinib (Cotellic; GDC-0973; cobimetinib hemifumarate) Melanoma Skin Cancer 2018 View  |  Download
Atezolizumab in combination with nab-paclitaxel as neoadjuvant treatment for early stage triple-negative breast cancer Atezolizumab (Tecentriq; MPDL3280A) , Nab-Paclitaxel (Abraxane; ABI 007; ABI-007) Breast cancer Breast Cancer 2018 View  |  Download
Atezolizumab in combination with Nab-paclitaxel for unresectable, locally advanced or metastatic triple-negative breast cancer – first line Atezolizumab (Tecentriq; MPDL3280A) , Nab-Paclitaxel (Abraxane; ABI 007; ABI-007) Breast cancer Breast Cancer 2018 View  |  Download
Avacopan in addition to standard of care for ANCA-associated vasculitis Avacopan (CCX168) Anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) Cardiovascular System , Immunology 2018 View  |  Download
Avelumab in combination with axitinib for advanced or metastatic renal cell carcinoma – first line Avelumab (Bavencio; MSB-0010718C) , Axitinib (Inlyta; AG-013736) Renal cell carcinoma (RCC) Renal Cancer 2018 View  |  Download
Avelumab with or without Pegylated Liposomal Doxorubicin (PLD) for Ovarian Cancer – second line Avelumab (Bavencio; MSB-0010718C) , Pegylated liposomal doxorubicin Epithelial ovarian cancer , Fallopian tube cancer , primary peritoneal cancer Female Reproductive Cancer 2018 View  |  Download
AVXS-101 for spinal muscular atrophy Onasemnogene abeparvovec (Zolgensma; AVXS-101; scAAV9.CB.SMN) Spinal muscular atrophy (SMA) Genetic Disorders , Musculoskeletal System 2018 View  |  Download
Axalimogene Filolisbac for Cervical Cancer – Beyond First Line Treatment Axalimogene filolisbac (ADXS11-001) Cervical cancer Female Reproductive Cancer 2018 View  |  Download
Medicines
Medicine Industry's Gateway to NICE
Support for Industry
Outputs & Publications